SOCRA CCRP Practice Exam (Sample)

Study Guide

Everything you need from our exam experts!

Table of Contents

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- **Practice answering questions under realistic conditions,**
- **Improve accuracy and speed,**
- **Review explanations to strengthen weak areas, and**
- **Approach the exam with greater confidence.**

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Don't worry about getting everything right, your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations, and take breaks to retain information better.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning.

7. Use Other Tools

Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There’s no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly — adapt the tips above to fit your pace and learning style. You've got this!

Questions

1. IRBs must develop SOPs for ensuring prompt reporting of which of the following?

A. Financial conflicts of interest

B. Changes in research activity

C. Publication of results

D. All meetings and discussions

2. How many days does a sponsor have to report withdrawal of FDA approval?

A. Immediately

B. Within 5 working days

C. Within 10 working days

D. Within 30 calendar days

3. What does the ICF document represent in clinical research?

A. Income and Cash Flow statement

B. Informed Consent Form

C. Internal Control Framework

D. Initial Certification Form

4. How often must an IRB renew its registration?

A. Every year

B. Every 2 years

C. Every 3 years

D. Every 5 years

5. Which regulations dictate adverse event and serious adverse event reporting?

A. 21 CFR 312.32 and 21 CFR 812.46

B. 21 CFR 314.80 and 21 CFR 600.80

C. 21 CFR 210 and 21 CFR 211

D. ICH E6 and ICH E2A

6. What is a key item of documentation for IRB members?

A. Social Security Number

B. Phone number

C. Degrees

D. Favorite color

7. FDA Form 3455 is used for what?

A. Certification of no financial interest by investigators

B. Disclosure of financial interests by clinical investigators

C. Application for drug testing in humans

D. Emergency use authorization of investigational drugs

8. What factor can necessitate financial disclosure?

A. Any payment from the sponsor

B. Compensation to PI affected by study outcome

C. Travel expenses covered by the sponsor

D. Any association with the sponsor

9. How should an investigator reconcile investigational product received from the sponsor?

A. By ensuring it is used as quickly as possible

B. By returning all unused product immediately

C. By reconciling the received product as per regulations

D. By logging its use in personal diaries

10. When is expedited review by an IRB appropriate?

A. When the study involves more than minimal risk

B. For all studies involving children

C. If the study involves no more than minimal risk

D. Only for initial review of the study

Answers

1. B
2. B
3. B
4. C
5. A
6. C
7. B
8. B
9. C
10. C

Explanations

1. IRBs must develop SOPs for ensuring prompt reporting of which of the following?

A. Financial conflicts of interest

B. Changes in research activity

C. Publication of results

D. All meetings and discussions

An IRB must develop SOPs for ensuring prompt reporting of changes in research activity. This is because changes in research activity can impact the safety and well-being of research participants and may require additional ethical review. Financial conflicts of interest (A) do not necessarily require prompt reporting, as long as they are properly managed and disclosed. Publication of results (C) and all meetings and discussions (D) are not under the jurisdiction of an IRB, and thus do not require SOPs for reporting.

2. How many days does a sponsor have to report withdrawal of FDA approval?

A. Immediately

B. Within 5 working days

C. Within 10 working days

D. Within 30 calendar days

After FDA approval, the sponsor has 5 working days to report any withdrawal of approval. This is the most timely option compared to the other choices. While option A says "immediately," this is too vague and does not specify a specific timeframe. Option C and D mention "working days" and "calendar days" respectively, which can cause confusion as to the exact timeframe allowed for reporting. Therefore, option B is the best choice as it clearly states within 5 working days.

3. What does the ICF document represent in clinical research?

A. Income and Cash Flow statement

B. Informed Consent Form

C. Internal Control Framework

D. Initial Certification Form

The ICF document represents the Informed Consent Form in clinical research. This is a form that outlines the purpose and procedures of the study, potential risks and benefits, and the rights of the participant. This form is necessary to ensure that participants fully understand the study and give their voluntary consent to participate. The other options are incorrect as they do not relate to clinical research or the purpose of an ICF. Option A (Income and Cash Flow statement) is a financial document, option C (Internal Control Framework) is a management tool used in companies, and option D (Initial Certification Form) is not commonly used in clinical research.

4. How often must an IRB renew its registration?

A. Every year

B. Every 2 years

C. Every 3 years

D. Every 5 years

Research involving human subjects is subject to review by an Institutional Review Board (IRB). IRBs must register with the federal government and must renew their registration every three years. Options A and D are incorrect because one year is too frequent and five years is too infrequent for an IRB to renew its registration. Option B is incorrect because it appears to be a compromise answer between the two extremes, but it does not match the actual requirement of every three years. Therefore, option C is the most accurate answer.

5. Which regulations dictate adverse event and serious adverse event reporting?

A. 21 CFR 312.32 and 21 CFR 812.46

B. 21 CFR 314.80 and 21 CFR 600.80

C. 21 CFR 210 and 21 CFR 211

D. ICH E6 and ICH E2A

21 CFR 312.32 and 21 CFR 812.46 specifically address adverse event and serious adverse event reporting in clinical trials under the FDA. Option B (21 CFR 314.80 and 21 CFR 600.80) relates to post-marketing reporting for drug and biologic products, but does not cover clinical trials. Option C (21 CFR 210 and 21 CFR 211) refer to general good manufacturing practice regulations, not reporting requirements. Option D (ICH E6 and ICH E2A) are international guidelines, but do not have the same legal authority as FDA regulations. Therefore, these options are not as relevant to adverse event and serious adverse event reporting as option A.

6. What is a key item of documentation for IRB members?

A. Social Security Number

B. Phone number

C. Degrees

D. Favorite color

Degrees are a key item of documentation for IRB members because they indicate the level of education and expertise of the member. Social Security Numbers, phone numbers, and favorite colors are not relevant to the IRB's work and do not provide any useful information about the member's qualifications or background. While other documents such as resumes or work experience may also be important, degrees specifically demonstrate the individual's academic achievements and knowledge in their field.

7. FDA Form 3455 is used for what?

A. Certification of no financial interest by investigators

B. Disclosure of financial interests by clinical investigators

C. Application for drug testing in humans

D. Emergency use authorization of investigational drugs

FDA Form 3455 is used to disclose financial interests by clinical investigators when conducting clinical trials. Option A is not correct because it refers to a different form, FDA Form 3454, which is used to certify that the investigators have no financial interests. Option C is incorrect because FDA Form 3455 is not used for drug testing in humans, but rather for the disclosure of financial interests. Option D is also incorrect as it pertains to a different form, FDA Form 1572, which is used for emergency use authorization of investigational drugs. It is important for clinical investigators to disclose their financial interests to avoid any potential conflicts of interest.

8. What factor can necessitate financial disclosure?

A. Any payment from the sponsor

B. Compensation to PI affected by study outcome

C. Travel expenses covered by the sponsor

D. Any association with the sponsor

Financial disclosure refers to the reporting of financial interests and relationships related to a particular study. In this case, the question asks for the factor that may require financial disclosure. Option A and C are incorrect because they both suggest financial transactions or benefits from the sponsor, but they do not directly address the need for disclosure. Option D implies a connection with the sponsor, but this alone does not necessarily require financial disclosure. Only option B refers to compensation specifically for the principal investigator (PI) and how it may be impacted by the outcome of the study, making it the correct answer in this context.

9. How should an investigator reconcile investigational product received from the sponsor?

A. By ensuring it is used as quickly as possible

B. By returning all unused product immediately

C. By reconciling the received product as per regulations

D. By logging its use in personal diaries

An investigator should reconcile investigational product received from the sponsor by following regulations. This includes accurately documenting and recording the received product, including any unused product. This helps ensure proper use and accountability of the investigational product. Neither A or D provide a thorough and regulatory-compliant method of reconciling the received investigational product. B is also incorrect as returning unused product immediately does not involve proper documentation and tracking required by regulations.

10. When is expedited review by an IRB appropriate?

A. When the study involves more than minimal risk

B. For all studies involving children

C. If the study involves no more than minimal risk

D. Only for initial review of the study

An expedited review by an IRB is appropriate when the study involves minimal risk to participants. This means that the study poses little to no harm or discomfort to the participants. Option A is incorrect because an expedited review may not be necessary if the study poses more than minimal risk. Option B is incorrect because expedited review is not solely based on the involvement of children, but rather on the level of risk in the study. Option D is incorrect because expedited review can be used for both initial and continuing review of a study.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://ccrpsocraexam.examzify.com

We wish you the very best on your exam journey. You've got this!